Christopher Freeburn

Christopher Freeburn

Christopher T. Freeburn has been a financial writer and editor for more than 10 years. He has worked at industry trade publications like Food Logistics, ChemicalWeek and Institutional Investor. His freelance articles have appeared in a variety of magazines, including Technology Review, Audubon and USA Weekend. He lives in Westchester County, just outside New York City.”

Recent Articles

GM, Ford April Sales Fall, Chrysler’s Rise

General Motors and Ford saw vehicle sales slide by single digits during April, while Chrysler and Volkswagen posted doubt-digit sales jumps.

Pfizer: Profits Drop, Beat Forecasts

Pfizer's first-quarter earnings and revenue declined, led by dropping sales for Lipitor, but beat analysts’ forecasts, even as it lowered its outlook.

Monday Apple Rumors: China iPhone Sales to Hit 35 Million

The spread of 3G service will speed sales; Apple in talks with streaming service EPIX; hiring for a new Israel R&D center moves forward.

B&N Shares Spike on Microsoft Stake

Microsoft will invest $300 million into Barnes & Noble’s Nook e-books unit, in exchange for an 18% share of the new subsidiary.

P&G Shares Fall 4% as Outlook Declines

Procter & Gamble lowered expectations for its full fiscal year, which ends in June, blaming slow sales and rising costs, sending its shares down 4%.

Friday Apple Rumors: Austin Facility ‘in Peril’

A planned Austin, Texas, facility is endangered by a lagging incentive-approval process, Apple's sales in China soar, and the Mac App Store passes 10,000 apps.

GDP Slows to 2.2%, Below Forecasts

The U.S. growth rate continued expanding in Q1, but less briskly and missing economists’ forecasts of at least 2.5% growth.

Overseas Corruption Probes: Beyond Wal-Mart

A total of 150 companies and individuals are under scrutiny for violations of the Foreign Corrupt Practices Act.

Thursday Apple Rumors: Jobs Was Behind an Ad-Supported OS

Plus: iPads attract first-time Apple customers, and Apple’s Cupertino employees to get a secure cafeteria -- no outsiders allowed.

AstraZeneca CEO Resigns, Shares Drop

CEO David Brennan departs after the company reported lower earnings and sales for the last quarter and a diminished outlook for the year.